肿瘤细胞上存在一种名为“PD-L1”的蛋白,这个“小兵”极具迷惑性,会让免疫检查点PD-1误以为肿瘤细胞是“自己人”,进而不去攻击肿瘤细胞,使它逃脱了免疫系统的灭杀。 于是,在面对肿瘤攻击时,人们迫切需要为PD-1配置一名帮手,纠正它...
[2] Tang Q, Chen Y, Li X, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022, 13: 964442. doi: 10.3389/fimmu.2022.964442. [3] Wang Y, Zhou S, Yang F, et al. Trea...
诱导PD-L1二聚并抑制PD-1:PD-L1相互作用 通过晶体结构研究，一些化合物被证明通过诱导PD-L1二聚化来抑制PD-1:PD-L1相互作用。例如BMS的小分子抑制剂倾向于首先与一种PD-L1单体相互作用，然后形成二聚体，以获得稳定性优势。而Incyte和Arbutus还利用了PD-L1二聚体中固有的C2对称性，通过对称化其分子来获得更大...
PD-1PD-L1immunotherapyImmune checkpoint inhibitors (CIs) have changed the landscape of tumor immunotherapy. Glioblastoma (GBM) remains the most common primary malignant brain tumor in adults and has a very poor prognosis. Due to the high invasiveness and aggressiveness of GBM, there is considerable...
Moreover, current single-use immune checkpoint inhibitors (ICIs), such as programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors, are only effective for some advanced CRC patients with microsatellite instability-high (MSI-H), and most patients may be unable to...
PD-1/PD-L1等免疫检查点蛋白的发现代表了肿瘤免疫治疗领域的重大突破,靶向这些免疫检查点蛋白的人源化单克隆抗体即免疫检查点抑制剂(Immune Checkpoint Inhibitors,ICIs)已成功用于包括肺癌、食管癌、胃癌、尿路上皮癌、肝癌、结直肠癌、乳腺癌、经典型霍奇金淋巴瘤及恶性黑色素细胞瘤等肿瘤的治疗之中,以PD-1/PD-...
那么不同癌种，两类免疫检查点抑制剂是否疗效有区别呢？免疫检查点抑制剂（immune checkpoint inhibitors,...
This study aimed to investigate whether microbiota-host interactions contribute to PD-1/PD-L1 inhibitor-related cardiotoxicity. 方法:A mouse model of immune checkpoint inhibitor-related cardiotoxicity was constructed by PD-1/PD-L1 inhibitor BMS-1 (5 and 10 mg/kg), and cardiomyocyte apoptosis and ...
(Monash University)公共卫生学院张麟教授课题组合作,在《International Journal of Surgery》(影响因子 15.3)发表了题为 「Toxicities associated with immune checkpoint inhibitors: a systematic study」 的回顾性系统研究,旨在调查癌症患者对 PD-1/PD-L1 抑制剂相关毒性的易感性,并建立 PD-1/PD-L1 抑制剂相关毒...
1.D. B. Doroshow et al., PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol 18, 345-362 (2021).2. R. S. Finn et al., Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382, 1894-1905 (2020).3. L. Paz-Ares et...